$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

$jazz Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000123252416000384 Filed on November 08, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$396.6M	$374.2M	$340.9M
YoY Change	16.35%	9.77%	11.18%
Cost Of Revenue	$33.70M	$24.30M	$28.40M
YoY Change	40.42%	-14.44%	5.19%
Gross Profit	$359.0M	$347.3M	$310.4M
YoY Change	13.99%	11.9%	11.88%
Gross Profit Margin	90.5%	92.82%	91.05%
Selling, General & Admin	$125.6M	$124.4M	$104.0M
YoY Change	1.05%	19.53%	11.28%
% of Gross Profit	34.99%	35.81%	33.52%
Research & Development	$44.20M	$47.80M	$50.78M
YoY Change	49.83%	-5.88%	126.48%
% of Gross Profit	12.31%	13.76%	16.36%
Depreciation & Amortization	$29.80M	$29.60M	$28.70M
YoY Change	12.45%	3.14%	-11.42%
% of Gross Profit	8.3%	8.52%	9.25%
Operating Expenses	$195.9M	$237.9M	$209.3M
YoY Change	10.37%	13.66%	-15.77%
Operating Profit	$163.1M	$136.3M	$131.5M
YoY Change	18.68%	3.59%	126.64%
Interest Expense	-$14.50M	-$18.50M	-$12.65M
YoY Change	43.56%	46.23%	-12.94%
% of Operating Profit	-8.89%	-13.58%	-9.62%
Other Income/Expense, Net		-$749.0K	-$977.0K
YoY Change		-23.34%
Pretax Income	$151.0M	$116.4M	$117.9M
YoY Change	56.48%	-1.3%	135.86%
Income Tax	$26.80M	$26.44M	$29.95M
% Of Pretax Income	17.75%	22.72%	25.4%
Net Earnings	$116.7M	$89.83M	$87.96M
YoY Change	41.0%	2.12%	241.38%
Net Earnings / Revenue	29.42%	24.01%	25.8%
Basic Earnings Per Share	$1.95	$1.49	$1.43
Diluted Earnings Per Share	$1.91	$1.45	$1.39
COMMON SHARES
Basic Shares Outstanding	59.89M shares	60.44M shares	61.44M shares
Diluted Shares Outstanding		61.80M shares	63.15M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$426.0M	$426.0M	$998.9M
YoY Change	-56.92%	-57.35%	73.72%
Cash & Equivalents	$366.0M	$366.6M	$998.9M
Short-Term Investments	$60.00M	$59.40M	$999.0M
Other Short-Term Assets	$29.31M	$24.52M	$18.97M
YoY Change	53.88%	29.25%	3.31%
Inventory	$34.05M	$32.35M	$30.02M
Prepaid Expenses	$24.50M	$23.30M	$21.28M
Receivables	$234.2M	$238.1M	$195.8M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$748.1M	$744.2M	$1.315B
YoY Change	-40.52%	-43.4%	49.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$107.5M	$99.90M	$83.45M
YoY Change	25.61%	19.71%	88.78%
Goodwill	$893.8M	$928.0M	$669.0M
YoY Change	36.02%	38.71%	-7.64%
Intangibles	$3.012B	$3.110B	$1.271B
YoY Change	154.05%	144.77%	-18.05%
Long-Term Investments
YoY Change
Other Assets	$14.06M	$37.76M	$25.39M
YoY Change	51.66%	48.72%	88.35%
Total Long-Term Assets	$4.052B	$4.186B	$2.149B
YoY Change	95.29%	94.77%	-12.95%
TOTAL ASSETS
Total Short-Term Assets	$748.1M	$744.2M	$1.315B
Total Long-Term Assets	$4.052B	$4.186B	$2.149B
Total Assets	$4.800B	$4.931B	$3.464B
YoY Change	44.04%	42.33%	3.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$22.42M	$17.63M	$29.12M
YoY Change	2.79%	-39.48%	-1.84%
Accrued Expenses	$193.3M	$172.4M	$166.4M
YoY Change	17.8%	3.63%	3.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$36.09M	$36.09M	$117.6M
YoY Change	-3.97%	-69.3%	1145.12%
Total Short-Term Liabilities	$257.4M	$232.9M	$340.2M
YoY Change	13.57%	-31.55%	52.05%
LONG-TERM LIABILITIES
Long-Term Debt	$1.994B	$2.147B	$1.172B
YoY Change	73.22%	83.21%	-11.96%
Other Long-Term Liabilities	$112.6M	$106.1M	$59.67M
YoY Change	62.62%	77.82%	77.6%
Total Long-Term Liabilities	$2.106B	$2.253B	$1.232B
YoY Change	72.62%	82.95%	-9.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$257.4M	$232.9M	$340.2M
Total Long-Term Liabilities	$2.106B	$2.253B	$1.232B
Total Liabilities	$2.364B	$2.486B	$1.572B
YoY Change	63.37%	58.17%	-1.05%
SHAREHOLDERS EQUITY
Retained Earnings	$528.9M	$315.4M	$260.2M
YoY Change	74.74%	21.23%	-850.52%
Common Stock	$1.665B	$1.635B	$1.534B
YoY Change	6.55%	6.61%	7.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.877B	$1.831B	$1.563B
YoY Change
Total Liabilities & Shareholders Equity	$4.800B	$4.931B	$3.464B
YoY Change	44.04%	42.33%	3.49%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	$116.7M	$89.83M	$87.96M
YoY Change	41.0%	2.12%	241.38%
Depreciation, Depletion And Amortization	$29.80M	$29.60M	$28.70M
YoY Change	12.45%	3.14%	-11.42%
Cash From Operating Activities	$180.7M	$133.0M	$175.1M
YoY Change	50.96%	-24.04%	35.0%
INVESTING ACTIVITIES
Capital Expenditures	-$1.200M	-$17.40M	-$5.200M
YoY Change	-64.71%	234.62%	-93.74%
Acquisitions
YoY Change
Other Investing Activities	-$600.0K	-$1.514B	$0.00
YoY Change
Cash From Investing Activities	-$1.900M	-$1.531B	-$5.200M
YoY Change	-44.12%	29342.31%	-93.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-172.0M	895.2M	-94.50M
YoY Change	38.93%	-1047.3%	-135.89%
NET CHANGE
Cash From Operating Activities	180.7M	133.0M	175.1M
Cash From Investing Activities	-1.900M	-1.531B	-5.200M
Cash From Financing Activities	-172.0M	895.2M	-94.50M
Net Change In Cash	6.800M	-502.8M	75.40M
YoY Change	-190.67%	-766.84%	-75.66%
FREE CASH FLOW
Cash From Operating Activities	$180.7M	$133.0M	$175.1M
Capital Expenditures	-$1.200M	-$17.40M	-$5.200M
Free Cash Flow	$181.9M	$150.4M	$180.3M
YoY Change	47.77%	-16.58%	-15.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001232524
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59892335	shares
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	2350000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	8993000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	3323000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4642000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-682000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3595000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4920000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1112000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.273
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-977000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-646000	USD
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Jazz Pharmaceuticals plc
	dei	Trading Symbol TradingSymbol	JAZZ
CY2015Q4	jazz	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	1601000	USD
CY2016Q3	jazz	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	6310000	USD
CY2015Q4	jazz	Accrued Construction In Progress AccruedConstructionInProgress	1637000	USD
CY2016Q3	jazz	Accrued Construction In Progress AccruedConstructionInProgress	929000	USD
CY2015Q4	jazz	Accrued Interest AccruedInterest	4043000	USD
CY2016Q3	jazz	Accrued Interest AccruedInterest	2607000	USD
CY2015Q4	jazz	Accrued Inventory Related Liabilities AccruedInventoryRelatedLiabilities	1017000	USD
CY2016Q3	jazz	Accrued Inventory Related Liabilities AccruedInventoryRelatedLiabilities	4746000	USD
CY2015Q4	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	67454000	USD
CY2016Q3	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	71472000	USD
CY2015Q4	jazz	Capital Redemption Reserve CapitalRedemptionReserve	471000	USD
CY2016Q3	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	USD
CY2015Q4	jazz	Contract Claim Settlement Liabilities Current ContractClaimSettlementLiabilitiesCurrent	18000000	USD
CY2016Q3	jazz	Contract Claim Settlement Liabilities Current ContractClaimSettlementLiabilitiesCurrent	0	USD
CY2015Q3	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	28385000	USD
	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	78496000	USD
CY2016Q3	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	24311000	USD
	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	71730000	USD
CY2015Q4	jazz	Entity Wide Accounts Receivable Major Customers Percentage EntityWideAccountsReceivableMajorCustomersPercentage	0.90
CY2016Q3	jazz	Entity Wide Accounts Receivable Major Customers Percentage EntityWideAccountsReceivableMajorCustomersPercentage	0.90
CY2015Q3	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	0	USD
	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	-16815000	USD
CY2016Q3	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	-638000	USD
	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	-638000	USD
CY2015Q4	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2016Q3	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2015Q4	jazz	Number Of Customers With Significant Accounts Receivable Balance NumberOfCustomersWithSignificantAccountsReceivableBalance	5	Customer
CY2016Q3	jazz	Number Of Customers With Significant Accounts Receivable Balance NumberOfCustomersWithSignificantAccountsReceivableBalance	5	Customer
	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	0	USD
	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	23750000	USD
	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	4021000	USD
	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	1764000	USD
CY2015Q3	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	2118000	USD
	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	6027000	USD
CY2016Q3	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	2560000	USD
	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	6705000	USD
CY2015Q4	jazz	Sales Return Reserve SalesReturnReserve	6110000	USD
CY2016Q3	jazz	Sales Return Reserve SalesReturnReserve	5010000	USD
	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	34025000	USD
	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	17951000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21807000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	17626000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	209685000	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	238072000	USD
CY2015Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	35595000	USD
CY2016Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	39768000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	164070000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	172418000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3038000	USD
CY2016Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4615000	USD
CY2015Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4211000	USD
CY2016Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6791000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23680000	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	29663000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-267472000	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-235376000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1562900000	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1635431000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	25402000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	20595000	USD
	us-gaap	Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation	320000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	67729000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	75176000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23114000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	67233000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24874000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74490000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	16456000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	47511000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	17619000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	53077000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	17348000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16418000	USD
CY2015Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26127000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	74472000	USD
CY2016Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26453000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	75832000	USD
CY2015Q4	us-gaap	Assets Assets	3343604000	USD
CY2016Q3	us-gaap	Assets Assets	4930581000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	1257667000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	744229000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	988785000	USD
CY2016Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	425985000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2016Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	988785000	USD
CY2016Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	425985000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	684042000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	998859000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	988785000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	366567000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	314817000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-622218000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	104725000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	137594000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	101757000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	304644000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	14000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	5000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	104739000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	137599000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	101757000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	304644000	USD
CY2016Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2296875000	USD
CY2015Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	7209000	USD
CY2016Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	10258000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-25368000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-16462000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1370000	USD
CY2016Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1499000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3721000	USD
CY2016Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2881000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	122863000	USD
CY2016Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	0	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	294485000	USD
CY2016Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	725358000	USD
	us-gaap	Depreciation Depreciation	7143000	USD
	us-gaap	Depreciation Depreciation	8165000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.04
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.49
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.91
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.41
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.40
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-8035000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-9647000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-659000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14117000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	9555000	USD
CY2015Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.254
CY2016Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.250
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.285
CY2015Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	6658000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	19722000	USD
CY2016Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	7255000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	21413000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	-320000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	-320000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	332602000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	411306000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	703276000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	26671000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	102381000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	103582000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	103805000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	106683000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1335903000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1557704000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1003301000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1146398000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-117000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	657139000	USD
CY2016Q3	us-gaap	Goodwill Goodwill	927993000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	261783000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	9071000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	117905000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	339424000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	116368000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	381133000	USD
CY2015Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2016Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-103000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-103000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29945000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	92651000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29120000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	108482000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4826000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4288000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10661000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	28274000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	713032000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	18469000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	18352000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5298000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8512000	USD
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1719000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1927000	shares
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1207000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1291000	shares
CY2015Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1518208000	USD
CY2016Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3521745000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1185606000	USD
CY2016Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3110439000	USD
CY2015Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-12650000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-44707000	USD
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-18498000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-42811000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5007000	USD
CY2016Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9328000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	19451000	USD
CY2016Q3	us-gaap	Inventory Net InventoryNet	32351000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2608000	USD
CY2016Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2357000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11836000	USD
CY2016Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	20666000	USD
CY2015Q4	us-gaap	Investments Investments	0	USD
CY2016Q3	us-gaap	Investments Investments	59418000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3343604000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4930581000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	226642000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	232859000	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	1188444000	USD
CY2016Q3	us-gaap	Long Term Debt LongTermDebt	2183473000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	37587000	USD
CY2016Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	36094000	USD
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	2075801000	USD
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	76699000	USD
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	58652000	USD
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	40606000	USD
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	36094000	USD
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	9023000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1150857000	USD
CY2016Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2147379000	USD
	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	60000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-90462000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1747441000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	412202000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	409841000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	87960000	USD
	us-gaap	Net Income Loss NetIncomeLoss	246774000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	87145000	USD
	us-gaap	Net Income Loss NetIncomeLoss	272548000	USD
CY2015Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000	USD
CY2016Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	209340000	USD
	us-gaap	Operating Expenses OperatingExpenses	582330000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	237928000	USD
	us-gaap	Operating Expenses OperatingExpenses	665202000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	131532000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	401592000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	136253000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	426150000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	128841000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	9606000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	10375000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	11901000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	15465000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	78037000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	3457000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	21364000	USD
CY2016Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30170000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	19047000	USD
CY2016Q3	us-gaap	Other Assets Current OtherAssetsCurrent	24517000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	27548000	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37764000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	16779000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-109174000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	14612000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	32096000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	16779000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-109174000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	14612000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	32096000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	69253000	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106101000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3834000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1460000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	302686000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	315415000	USD
CY2015Q3	us-gaap	Revenues Revenues	340872000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-749000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1568000	USD
CY2015Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	0	USD
CY2016Q3	us-gaap	Other Short Term Investments OtherShortTermInvestments	59418000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	21302000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	259819000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	25402000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	20595000	USD
	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	60000	USD
	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1502443000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	150000000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	64693000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	32591000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	6555000	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	20699000	USD
CY2016Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	23304000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	33703000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	898960000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	994777000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	34025000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	17951000	USD
CY2015Q3	us-gaap	Profit Loss ProfitLoss	87960000	USD
	us-gaap	Profit Loss ProfitLoss	246773000	USD
CY2016Q3	us-gaap	Profit Loss ProfitLoss	87145000	USD
	us-gaap	Profit Loss ProfitLoss	272548000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	109252000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	129561000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	85572000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	99898000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	80000000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	896363000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	19282000	USD
CY2015Q3	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
CY2016Q3	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	15000000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	23750000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50784000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	105798000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47796000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	118139000	USD
	us-gaap	Revenues Revenues	983922000	USD
CY2016Q3	us-gaap	Revenues Revenues	374181000	USD
	us-gaap	Revenues Revenues	1091352000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	338754000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	977895000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	371621000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1084647000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	104044000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	323564000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	124368000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	375751000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	67233000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	74490000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	21302000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	259819000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1371208000	USD
CY2015Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1563477000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1598646000	USD
CY2016Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1716003000	USD
CY2015Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	1808000	USD
CY2016Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	5222000	USD
CY2016Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	23100000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63154000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63072000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61644000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61983000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61435000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61145000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60437000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60692000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and marketable securities. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable, and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001232524-16-000384-index-headers.html	Edgar Link	pending
0001232524-16-000384-index.html	Edgar Link	pending
0001232524-16-000384.txt	Edgar Link	pending
0001232524-16-000384-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
jazz-20160930.xml	Edgar Link	completed
jazz-20160930.xsd	Edgar Link	pending
jazz-20160930_cal.xml	Edgar Link	unprocessable
jazz-20160930_def.xml	Edgar Link	unprocessable
jazz-20160930_lab.xml	Edgar Link	unprocessable
jazz-20160930_pre.xml	Edgar Link	unprocessable
jazz2016q3doc.htm	Edgar Link	pending
jazzq32016ex102.htm	Edgar Link	pending
jazzq32016ex103.htm	Edgar Link	pending
jazzq32016ex104.htm	Edgar Link	pending
jazzq32016ex105.htm	Edgar Link	pending
jazzq32016ex106.htm	Edgar Link	pending
jazzq32016ex107.htm	Edgar Link	pending
jazzq32016ex108.htm	Edgar Link	pending
jazzq32016ex311.htm	Edgar Link	pending
jazzq32016ex312.htm	Edgar Link	pending
jazzq32016ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

2016 Q4 Form 10-Q Financial Statement

#000123252416000384 Filed on November 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ Jazz Pharmaceuticals PLC Stock $jazz

2016 Q4 Form 10-Q Financial Statement

#000123252416000384 Filed on November 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz